内容紹介
Clinical Benefit of Full-Dose Gemcitabine for Advanced Pancreatic Cancer Refractory to S-1+Gemcitabine
Summary
A 62-year-old man with pancreatic body cancer underwent distal pancreatectomy without adjuvant gemcitabine(GEM). Because the pancreatic cancer recurred 4 months after surgery, however, he was treated with combination chemotherapy(S-1+GEM at 750 mg/m2). Unfortunately, this combination regimen was ineffective; therefore S-1 was withdrawn and full-dose GEM was administered as second-line treatment. One year of full-dose GEM showed a significant clinical benefit, completely eliminating multiple pulmonary metastases even after a 3-month suspension of chemotherapy. Our findings suggest that GEM monotherapy is a useful mainstream treatment for advanced pancreatic cancer.
要旨
症例は62歳,男性。膵体尾部癌にて膵体尾部切除術を施行し,術後4か月で局所再発が出現した。S-1+gemcitabine併用療法(GEM 750 mg/m2)にて治療を開始後9か月のCTにて多発肺転移を認め,GEM単独療法(1,000 mg/m2)に変更後12か月でCT画像上CRの抗腫瘍効果を認めた。3か月後に治療を中止したが,9か月経過しCRを継続している。GEM単独療法は未だに進行膵癌治療の主流と思われる。
目次
Summary
A 62-year-old man with pancreatic body cancer underwent distal pancreatectomy without adjuvant gemcitabine(GEM). Because the pancreatic cancer recurred 4 months after surgery, however, he was treated with combination chemotherapy(S-1+GEM at 750 mg/m2). Unfortunately, this combination regimen was ineffective; therefore S-1 was withdrawn and full-dose GEM was administered as second-line treatment. One year of full-dose GEM showed a significant clinical benefit, completely eliminating multiple pulmonary metastases even after a 3-month suspension of chemotherapy. Our findings suggest that GEM monotherapy is a useful mainstream treatment for advanced pancreatic cancer.
要旨
症例は62歳,男性。膵体尾部癌にて膵体尾部切除術を施行し,術後4か月で局所再発が出現した。S-1+gemcitabine併用療法(GEM 750 mg/m2)にて治療を開始後9か月のCTにて多発肺転移を認め,GEM単独療法(1,000 mg/m2)に変更後12か月でCT画像上CRの抗腫瘍効果を認めた。3か月後に治療を中止したが,9か月経過しCRを継続している。GEM単独療法は未だに進行膵癌治療の主流と思われる。